Sun pharma Key facts/ Numbers / details/ history / market/ business/ Analysis of annual report/ Key managerial person/ Indian pharma/ Ranbaxy laboratories

1. By: Mithlesh Kumar
Camithlesh@live.com

2. Introduction
Founded : 1983
Registration date: 1st March 1993
Listing year: 1994
Founder: Dilip Sanghvi
Headquartered: Mumbai, India
Industry: Pharma
Traded as: BSE 524715, NSE SUNPHARMA
Key people: Dilip Sanghvi
Products: Formulated drug, API & OTC products

3. Key Facts
• Number of Markets Served: 150
• Number of Brands: 30
• Number of manufacturing location: 48
• Number of employees worldwide: 32700
• Product Marketed: 2000
• Global Revenue for F.Y 14-15 : 4.5 Billion
• Sun’s Business Share:-
 USA- 50%
 India Branded Generic- 24%
 Emerging market- 14%
 Western Europe/ Canada/Australia/Newz. – 8%
 API – 4%

4. Achievements
• 5th Largest generic pharma company in world
• 5th Largest generic pharma company in USA
(Biggest Pharma market)
• 3rd Largest dermatology company in USA.
• India’s Largest pharma company
• Serving 9% of Indian pharma market
• Reach in 150 + Countries
• Largest India pharma company in emerging
market

5. Key Performance Indicator
Figure in 'Crores
.
Financial year
05-06
Financial year
14-15
CAGR 10 Years
Financial year
13-14
Growth Last
year
Total income 1800 28000 35% 16000 75%
Net Profit 573 4540 26% 3141 45%
R&D Expense 201 1955 1041 88%
Reserve & Surplus 1500 25300 37% 18317 38%
Net Asset Block 856 9000 5000
EPS/Share 2.4 18.9 13.1
R&D Expeses (as
% to Sales)
11% 7% 7%

6. Key Acquisitions
List of Key Acquisitions by Sun Pharma
Acquired Ranbaxy Laboratories (Made 5th largest company in world + No.1 Pharma co. in
India)
GSK opiates business
Licensing agreement with Merck for MK-22
Acquired Pharmalucenses
Formulation of Sun-Intrexon JV
Acquisition of URG Generic Business- Adds 107 products to the cart
Acquired DUSA pharma
Formulation of SUN-MSD JV
Acquired TARO Israel
Acquired Chattem Chemicals
Acquired assets of Able Labs
Acquired Caraco

7. Merger of Sun Pharma & Ranbaxy
Key Facts & Number
Sun Targeted $ 300 Million synergy by financial year 2018 due to merger with
Ranbaxy
Daichi retained 8.9% Equity stake after merger which they divested later
Face value of Sun’s share= 1 Rs.
Face value of Ranbaxy’s share at the time of merger = 5 Rs.
Book value of Sun’s share against face value of 1 Rs.- 107 Rs.
Market value of Sun’s share- 950 Rs.
Ranbaxy’s registered office state- Punjab, Sun’s Registered office state- Gujarat
Clearance of merger from Gujarat high court- 14th Nov. 2014 & Punjab’s high
court- 24th March 2015
Swap ratio used for Sun-Ranbaxy merger- .8 share of Sun given for 1 share of
Ranbaxy
Bonus declared after the merger by Sun Pharma- 1:1

8. Sun Pharma- Key Managerial Person
Name No. of shares hold by
the individuals (of
total share)
Role Salary As per the
financial Statement
Israel Makov Nil Other Director 4.99 Lakhs Rs.
Dilip Sanghvi 11.16% Managing Director 2.93 Crore Rs.
Shailesh Desai .18% Whole Time Director 92 Lakhs Rs.
Sudhir K Valia .74% Whole Time Director 3.05 Crore Rs.
S. Mohanchand Almost Nil % Other Director 8.5 Lakh Rs.
Hasmukh K
Shah
Nil Other Director 9 Lakhs Rs.
Keki M Mistri Almost Nil (41350
Shares)
Other Director 5.5 Lakhs Rs.
Ashwin R Dani Nil Other Director 6 Lakhs Rs.
Rekha Sethi Nil Other Director 5.5 Lakhs Rs.
Uday Baldota Almost Nil (22700
Shares)
Chief Financial Officer 2.5 Crore Rs.
Sunil Ajmera Nil Company Secretary 82 Lakhs Rs.

9. Sun Pharma- Manufacturing Locations
International Manufacturing Location
Wilmington MA
(America)
Billerica, MA
(America)
Ontario (Canada) New Jersey (USA) Aurora (USA)
Brayn (USA) Tennessee
(USA)
Iztapalapa
(Mexico)
Rio De Genaro
(Brazil)
Goiania (Brazil)
Giza (Egypt) Halifa (Israel) Cashel (Ireland) Casablanca
(Morocco)
Tiszavasvari
(Hungary)
Cluj (Romania) Bangladesh Kaula-lampur
(Malasiya)
Lagos (Nigeria) BE-Tabs (South
Africa)
Domestic Manufacturing Location
Baddi 2 Plants Jammu Batamandi Paonta Toansa
Mohali Halol Dahej Silvassa Ankleshwar
Panoli Karakhadi Sikkim Dewas Malanpur
Ahmednagar Dadra Goa Maduranthakam

10. Sun Pharma- Shareholders
with more than 5% Shares
Dilip Sanghvi 11.2 % of the total share
outstanding
Viditi Investments Pvt. Ltd. 9.7 % of the total share
outstanding
Tejakiran Pharmachem Pvt.
Ltd.
9.4 % of the total share
outstanding
Family Investments Pvt. Ltd. 8.8 % of the total share
outstanding
Quality Investments Pvt. Ltd. 8.8 % of the total share
outstanding

11. Therapeutic Segments- In which
company deals
Therapeutic Details
Neuro- Psychiatry Deceases related to nervous system
Cardiology Decrease & Anomalies related to heart
Anti- Infective General anti- Invectives
Gastroenterology Stomach & Intestine problems
Dialectology Diabetes Area
Pain/ Analgesics Pain reliever like Volini
Gynecology Health of female reproductive system
Vitamin/Minerals & Nutrients Vitamin/Mineral etc supplements
Dermatology Skin Related
Respiratory Respiratory system related
Ophthalmology Eye Related
Others Antiseptic/ Cough/ OTC products etc.